Clinical trials: Oral Neoplasm, open to volunteers
Advanced Squamous Tumors
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy…
- Trial name
- NCT07241039
- Testing
- ABBV-711, Budigalimab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 220 people
- Sponsor
- AbbVie
EGFR Positive Non-small Cell Lung Cancer, Non Small Cell Lung Cancer
Osimertinib for Advanced EGFR-positive NSCLC Patients
Lung cancer is the leading cause of cancer incidence (11.6%) and mortality (18.4%) globally[1]. Development of targeted therapies in the context of precision medicine changed the way lung cancer was diagnosed and treated.
- Trial name
- NCT05037331
- Where
- Singapore
- Volunteers
- 58 people
- Sponsor
- National University Hospital, Singapore
Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Background: Oral hedgehog inhibitors vismodegib and sonidegib have been used for the treatment of locally advanced (laBCC), metastatic basal cell carcinoma (mBCC) and in basal cell nevus syndrome (BCNS) patients.
- Conditions
- Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Metastatic Basal Cell Carcinoma, Gorlin Syndrome
- Trial name
- NCT05463757
- Testing
- Vismodegib, Sonidegib
- Where
- 8 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 60 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Quality of Life, Objective Masticatory Performance
Prosthetic Rehabilitation and Its Influence on Masticatory Performance and QoL in Patients Treated for HNC
The main goal of this clinical trial (pilot study) is to evaluate whether prosthetic rehabilitation modifies objective masticatory performance, subjective masticatory performance, quality of life, salivary flow and pH in patients…
- Conditions
- Quality of Life, Objective Masticatory Performance, Subjective Masticatory Performance, Oral Health
- Trial name
- NCT06124222
- Testing
- Prosthetic oral rehabilitation
- Where
- Spain
- Volunteers
- 21 people
- Sponsor
- University of Barcelona
Thyroid Nodule
Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules
A multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of Prunella oral liquid in patients with benign thyroid nodules, which belongs to the…
- Trial name
- ESPTTN (NCT06423235)
- Testing
- regular dose of JiRui® Prunella oral liquid, 2x regular dose of JiRui® Prunella oral liquid
- Where
- 22 sites in China
- Volunteers
- 234 people
- Sponsor
- Xintian Pharmaceutical
Oral Mucositis (Ulcerative) Due to Radiation, Nasopharyngeal Carcinoma (NPC)
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
This clinical trial aims to understand whether taurine can prevent and reduce severe radiation-induced oral mucositis in patients with nasopharyngeal carcinoma undergoing radiotherapy.
- Trial name
- NCT07567742
- Testing
- Taurine
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Sun Yat-sen University
Acute Promyelocytic Leukemia (APL)
Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia
It is a non-randomized, multicenter, prospective study, aiming to treat patients with newly diagnosed acute promyelocytic leukemia with a combination of oral arsenic and atra, with low dose chemotherapy for those with high-risk…
- Trial name
- IC-APL2020 (NCT06982274)
- Testing
- Realgar-Indigo Naturalis Formulation
- Where
- Brazil
- Volunteers
- 115 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Breast Cancer
A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and preliminary efficacy of HP568 alone and in combination with palbociclib in patients with ER+/HER2- locally advanced or…
- Trial name
- NCT06757335
- Testing
- HP568, HP568 in combination with palbociclib
- Volunteers
- 204 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers
This clinical trial evaluates how propionate and butyrate supplementation alters intestinal health in healthy volunteers and whether it would be feasible to administer these supplements to patients undergoing allogeneic…
- Conditions
- Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT07611370
- Testing
- Biospecimen Collection, Microencapsulated Sodium Butyrate, Microencapsulated Sodium Propionate
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Non-Small Cell Lung Cancer
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20…
- Trial name
- NCT06046495
- Testing
- PLB1004
- Where
- 7 sites in United States
- Volunteers
- 81 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Acute Myeloid Leukemia
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white…
- Trial name
- REVIVAL (NCT07581002)
- Testing
- Pivekimab Sunirine, Venetoclax, Azacitidine
- Where
- 38 sites in United States, Austria and 5 more
- Volunteers
- 660 people
- Sponsor
- AbbVie
Swallowing-induced Pain
Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma
The goal of this clinical trial is to explore the effectiveness and adverse reactions of doxepin solution spray for alleviation of stubborn breakthrough pain induced by swallowing in patients receiving radiotherapy for…
- Trial name
- NCT06017895
- Testing
- doxepin solution
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Salivary Gland Carcinoma, Precision Therapy
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and…
- Trial name
- NCT06145308
- Testing
- Cohort 1 (HER2-positive, RC48-ADC), Cohort 2 (NTRK-fusion or NTRK-mutant), Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Peking Union Medical College
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
- Trial name
- NCT06799065
- Testing
- ATX-295, ATX-295 and bevacizumab (or biosimilar)
- Where
- 11 sites in United States
- Volunteers
- 218 people
- Sponsor
- Accent Therapeutics
HER2-positive Breast Cancer
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer…
- Trial name
- TUC-TOC (NCT05955170)
- Testing
- Tucatinib in Combination of Oral VP16 and trastuzumab
- Where
- 13 sites in France
- Volunteers
- 66 people
- Sponsor
- Institut Curie
Venous Thromboembolism, Active Cancer
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous…
- Trial name
- NEXT-CAT (NCT07852637)
- Testing
- edoxaban, Apixaban
- Where
- 12 sites in South Korea
- Volunteers
- 2,300 people
- Sponsor
- Samsung Medical Center
Preoperative, Sleep Disturbance
Preoperative Oral Midazolam to Postoperative Pain Relief in Sleep Disturbance or Anxiety Patients With Colorectal Cancer
Previous studies have indicated a high incidence of sleep disturbances and anxiety symptoms in individuals with colorectal cancers prior to undergoing surgery, leading to worsened postoperative pain, slower recovery, and higher…
- Conditions
- Preoperative, Sleep Disturbance, Anxiety, Midazolam
- Trial name
- POMPPR (NCT06407518)
- Testing
- Midazolam oral solution
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Oral Cancers
A Community Engagement Approach to Improving Communication With Black Men About Oral and Pharyngeal Cancers
1. Specific OPC patient communication (COPC) tool to address OPCs among Black men. 2. Assess the COPC tool's ability to improve dental providers' communication with Black men. 3.
- Trial name
- NCT07172776
- Testing
- oral cancer communication tool
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Oral Cavity Squamous Cell Carcinoma
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of…
- Trial name
- NCT06097468
- Testing
- NisinZ® P, Surgery (non-interventional, standard of care)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco